Spoken Alpha
PERRIGO Co plc
Perrigo manufactures and markets over-the-counter self-care products sold under both store brands and owned brands to retailers, wholesalers, and consumers in North America and Europe.
PERRIGO Co plc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.89B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PRGO.
$ curl https://api.spokenalpha.com/v1/companies/PRGOFAQ
Spoken Alpha indexes PRGO's earnings call transcripts at https://spokenalpha.com/companies/PRGO. Each call links to attributed speakers and parsed analyst Q&A. PERRIGO Co plc's own investor relations page is at https://investor.perrigo.com/.
PERRIGO Co plc (PRGO) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
PERRIGO Co plc (PRGO) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $0.57 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $0.50 | $0.31 | +61.3% | $1.02B | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $0.43 | $0.31 | +38.7% | $969.2M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $0.77 | $0.80 | -3.8% | $1.11B | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $0.80 | $0.75 | +6.7% | $1.04B | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.57 | $0.59 | -3.4% | $1.06B | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.60 | $0.57 | +5.3% | $1.04B | — | — | EODHD |
| Q4 FY2024 | 2025-02-26 | $0.36 | $0.95 | -62.1% | $1.14B | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $0.81 | $0.81 | 0.0% | $1.09B | — | — | EODHD |
| Q2 FY2024 | 2024-08-01 | $0.53 | $0.46 | +15.2% | $1.07B | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $0.29 | $0.23 | +26.1% | $1.08B | — | — | EODHD |
| Q4 FY2023 | 2024-02-26 | $0.86 | $0.83 | +3.6% | $1.16B | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $0.64 | $0.63 | +1.6% | $1.12B | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $0.63 | $0.51 | +23.5% | $1.19B | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $0.45 | $0.43 | +4.7% | $1.18B | — | — | EODHD |
| Q4 FY2022 | 2023-02-26 | $0.75 | $0.71 | +5.6% | $1.16B | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $0.56 | $0.67 | -16.4% | $1.10B | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $0.43 | $0.44 | -2.3% | $1.12B | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $0.33 | $0.42 | -21.4% | $1.07B | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $0.60 | $0.56 | +7.1% | $1.10B | — | — | EODHD |
Source: EODHD. PRGO reported actuals as published; sparse fields render as —.